[go: up one dir, main page]

EP2426108B1 - Verfahren und Zwischenverbindungen zur Herstellung kondensierter heterocyclischer Kinase-Hemmer - Google Patents

Verfahren und Zwischenverbindungen zur Herstellung kondensierter heterocyclischer Kinase-Hemmer Download PDF

Info

Publication number
EP2426108B1
EP2426108B1 EP11009425.7A EP11009425A EP2426108B1 EP 2426108 B1 EP2426108 B1 EP 2426108B1 EP 11009425 A EP11009425 A EP 11009425A EP 2426108 B1 EP2426108 B1 EP 2426108B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
alternatively
mmol
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11009425.7A
Other languages
English (en)
French (fr)
Other versions
EP2426108A1 (de
Inventor
Franck Raeppel
Ljubomir Isakovic
Stephen William Claridge
Michael Mannion
Lijie Zhan
Marie-Claude Granger
Arkadii Vaisburg
Miguel Nantel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of EP2426108A1 publication Critical patent/EP2426108A1/de
Application granted granted Critical
Publication of EP2426108B1 publication Critical patent/EP2426108B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/51—Acetal radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Definitions

  • This invention relates to intermediates that are useful in the manufacture of fused heterocyclic-type compounds, in particular thienopyridine-based kinase inhibitor compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type compounds, in particular thienopyridine-based kinase inhibitor compounds, particularly at an industrial level.
  • Fused heterocyclic-type compounds have been found to be useful to inhibit protein tyrosine kinase activity.
  • fused heterocyclic-type compounds such as thienopyridine-based compounds, have been found useful to inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling.
  • Fused heterocyclic-type compounds have been found to be useful in the treatment of cancer by inhibiting protein tyrosine kinase activity.
  • the pharmaceutical compositions that comprise these compounds are also useful in the treatment of diseases, other than cancer, which are associated with signal transduction pathways operating through growth factor and anti-angiogenesis receptors such as c-Met.
  • Tyrosine kinases may be classified as growth factor receptor (e.g. EGFR, PDGFR, FGFR and erbB2) or non-receptor (e.g. c-src and bcr-abl) kinases.
  • the receptor type tyrosine kinases make up about 20 different subfamilies.
  • the non-receptor type tyrosine kinases make up numerous subfamilies. These tyrosine kinases have diverse biological activity.
  • Receptor tyrosine kinases are large enzymes that span the cell membrane and possess an extracellular binding domain for growth factors, a transmembrane domain, and an intracellular portion that functions as a kinase to phosphorylate a specific tyrosine residue in proteins and hence to influence cell proliferation. Aberrant or inappropriate protein kinase activity can contribute to the rise of disease states associated with such aberrant kinase activity.
  • VEGF-A vascular endothelial growth factor A
  • Flt-1 fms-like tyrosine kinase receptor
  • KDR kinase insert domain-containing receptor
  • VEGF vascular endothelial growth factor
  • the binding of VEGF as a disulfide-linked homodimer stimulates receptor dimerization and activation of the RTK domain.
  • the kinase activity autophosphorylates cytoplasmic receptor tyrosine residues, which then serve as binding sites for molecules involved in the propagation of a signaling cascade.
  • KDR signaling is most extensively studied, with a mitogenic response suggested to involve ERK-1 and ERK-2 mitogen-activated protein kinases.
  • VEGF receptor signaling Disruption of VEGF receptor signaling is a highly attractive therapeutic target in cancer, as angiogenesis is a prerequisite for all solid tumor growth, and that the mature endothelium remains relatively quiescent (with the exception of the female reproductive system and wound healing).
  • a number of experimental approaches to inhibiting VEGF signaling have been examined, including use of neutralizing antibodies, receptor antagonists, soluble receptors, antisense constructs and dominant-negative strategies.
  • VEGF expression levels can themselves be elevated by numerous diverse stimuli and perhaps most importantly, the hypoxic state of tumors resulting from VEGFr inhibition, can lead to the induction of factors that themselves promote tumor invasion and metastasis thus, potentially undermining the impact of VEGF inhibitors as cancer therapeutics.
  • HGF hepatocyte growth factor
  • HGF receptor c-Met
  • HGF binding protein kinase
  • MAPK Ras/mitogen-activated protein kinase
  • Biological agents such as ribozymes, antibodies and antisense RNA targeting either HGF or Met have been shown to inhibit tumorogenesis ( Stabile et al., (2004) Gene Therapy, 11:325-335 ; Jiang et al., (2003) Clin. Cancer Res., 9:4274-4281 ; and Genentech US 6,214,344 ).
  • WO2007/054831A2 discloses fused heterocyclic kinase inhibitors.
  • anti-tumor and/or anti-angiogenic strategies or approaches that target either or both VEGF/VEGFr signaling and HGF/c-Met signaling may circumvent the ability of tumor cells to overcome VEGF inhibition alone and may represent improved cancer therapeutics.
  • This invention is directed to intermediates that are useful in the manufacture of fused heterocyclic-type compounds, in particular thienopyridine-based kinase inhibitor compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type compounds, in particular thienopyridine-based kinase inhibitor compounds.
  • the present invention provides a compound selected from the group consisting of
  • the present invention provides a use of a compound of the first aspect for preparing a fused heterocyclic-type compound or intermediates that are useful in the manufacture of the fused heterocyclic-type compound, wherein the fused heterocyclic-type compound has the formula:
  • This invention relates to intermediates that are useful in the manufacture of fused heterocyclic-type compounds, in particular thienopyridine-based kinase inhibitor compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type compounds, in particular thienopyridine-based kinase inhibitor compounds.
  • Fused heterocyclic-type compounds have been found to be useful to inhibit protein tyrosine kinase activity.
  • fused heterocyclic-type compounds such as thienopyridine-based compounds, have been found useful to inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling.
  • Fused heterocyclic-type compounds have been found to be useful in the treatment of cancer by inhibiting protein tyrosine kinase activity.
  • the pharmaceutical compositions that comprise these compounds are also useful in the treatment of diseases, other than cancer, which are associated with signal transduction pathways operating through growth factor and anti-angiogenesis receptors such as c-Met.
  • a bivalent linking moiety can be "alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical (e.g., -CH 2 -CH 2 -), which is equivalent to the term “alkylene.”
  • alkyl a divalent radical
  • aryl a divalent moiety that is required and is stated as being “aryl”
  • All atoms are understood to have their normal number of valences for bond formation (i.e ., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the oxidation state of the S).
  • a moiety may be defined, for example, as (A) a -B-, wherein a is 0 or 1. In such instances, when a is 0 the moiety is B- and when a is 1 the moiety is A-B-.
  • a C 5 -C 6 -heterocyclyl is a 5- or 6- membered ring having at least one heteroatom, and includes pyrrolidinyl (C 5 ) and piperazinyl and piperidinyl (C 6 );
  • C 6 -heteroaryl includes, for example, pyridyl and pyrimidyl.
  • hydrocarbyl refers to a straight, branched, or cyclic alkyl, alkenyl, or alkynyl, each as defined herein.
  • a "Co” hydrocarbyl is used to refer to a covalent bond.
  • C 0 -C 3 hydrocarbyl includes a covalent bond, methyl, ethyl, ethenyl, ethynyl, propyl, propenyl, propynyl, and cyclopropyl.
  • alkyl is intended to mean a straight chain or branched aliphatic group having from 1 to 12 carbon atoms, alternatively 1-8 carbon atoms, and alternatively 1-6 carbon atoms. Other examples of alkyl groups have from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms and alternatively 2-6 carbon atoms. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.
  • a "Co" alkyl (as in "C 0 -C 3 alkyl”) is a covalent bond.
  • alkenyl is intended to mean an unsaturated straight chain or branched aliphatic group with one or more carbon-carbon double bonds, having from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms, and alternatively 2-6 carbon atoms.
  • alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.
  • alkynyl is intended to mean an unsaturated straight chain or branched aliphatic group with one or more carbon-carbon triple bonds, having from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms, and alternatively 2-6 carbon atoms.
  • alkynyl groups include, without limitation, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
  • alkylene alkenylene
  • alkynylene alkynylene
  • alkylene groups include, without limitation, methylene, ethylene, propylene, and butylene.
  • alkenylene groups include, without limitation, ethenylene, propenylene, and butenylene.
  • alkynylene groups include, without limitation, ethynylene, propynylene, and butynylene.
  • Carbocycle as employed herein is intended to mean a cycloalkyl or aryl moiety.
  • cycloalkyl is intended to mean a saturated or unsaturated mono-, bi-, tri- or poly-cyclic hydrocarbon group having about 3 to 15 carbons, alternatively having 3 to 12 carbons, alternatively 3 to 8 carbons, alternatively 3 to 6 carbons, and alternatively 5 or 6 carbons.
  • the cycloalkyl group is fused to an aryl, heteroaryl or heterocyclic group.
  • cycloalkyl groups include, without limitation, cyclopenten-2-enone, cyclopenten-2-enol, cyclohex-2-enone, cyclohex-2-enol, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, etc.
  • heteroalkyl is intended to mean a saturated or unsaturated, straight chain or branched aliphatic group, wherein one or more carbon atoms in the group are independently replaced by a heteroatom selected from the group consisting of O, S, and N.
  • aryl is intended to mean a mono-, bi-, tri- or polycyclic aromatic moiety, for example a C 6 -C 14 aromatic moiety, for example comprising one to three aromatic rings.
  • the aryl group is a C 6 -C 10 aryl group, alternatively a C 6 aryl group.
  • aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, and fluorenyl.
  • aralkyl or "arylalkyl” are intended to mean a group comprising an aryl group covalently linked to an alkyl group. If an aralkyl group is described as “optionally substituted”, it is intended that either or both of the aryl and alkyl moieties may independently be optionally substituted or unsubstituted. Alternatively, the aralkyl group is (C 1 -C 6 )alk(C 6 -C 10 )aryl, including, without limitation, benzyl, phenethyl, and naphthylmethyl.
  • arylalkyl this term, and terms related thereto, is intended to indicate the order of groups in a compound as “aryl - alkyl”.
  • alkyl-aryl is intended to indicate the order of the groups in a compound as “alkyl-aryl”.
  • heterocyclyl is intended to mean a group which is a mono-, bi-, or polycyclic structure having from about 3 to about 14 atoms, wherein one or more atoms are independently selected from the group consisting of N, O, and S.
  • the ring structure may be saturated, unsaturated or partially unsaturated.
  • the heterocyclic group is non-aromatic, in which case the group is also known as a heterocycloalkyl.
  • one or more rings may be aromatic; for example one ring of a bicyclic heterocycle or one or two rings of a tricyclic heterocycle may be aromatic, as in indan and 9,10-dihydro anthracene.
  • heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, and morpholino.
  • the heterocyclic group is fused to an aryl, heteroaryl, or cycloalkyl group.
  • fused heterocycles include, without limitation, tetrahydroquinoline and dihydrobenzofuran. Specifically excluded from the scope of this term are compounds where an annular O or S atom is adjacent to another O or S atom.
  • the heterocyclic group is a heteroaryl group.
  • heteroaryl is intended to mean a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having, in addition to carbon atoms, between one or more heteroatoms independently selected from the group consisting of N, O, and S.
  • a heteroaryl group may be pyrimidinyl, pyridinyl, benzimidazolyl, thienyl, benzothiazolyl, benzofuranyl and indolinyl.
  • heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyl.
  • arylene is intended to mean an aryl, heteroaryl, or heterocyclyl group, respectively, as defined hereinabove, that is positioned between and serves to connect two other chemical groups.
  • heterocyclyls and heteroaryls include, but are not limited to, azepinyl, azetidinyl, acridinyl, azocinyl, benzidolyl, benzimidazolyl, benzofuranyl, benzofurazanyl, benzofuryl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzothienyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, benzoxazolyl, benzoxadiazolyl, benzopyranyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, coumarinyl, decahydroquinolinyl, 1,3-dioxolane, 2H
  • azolyl as employed herein is intended to mean a five-membered saturated or unsaturated heterocyclic group containing two or more hetero-atoms, as ring atoms, selected from the group consisting of nitrogen, sulfur and oxygen, wherein at least one of the hetero-atoms is a nitrogen atom.
  • azolyl groups include, but are not limited to, optionally substituted imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, and 1,3,4-oxadiazolyl.
  • Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-), nitro, halohydrocarbyl, hydrocarbyl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups. Examples of substituents, which are themselves not further substituted (unless expressly stated otherwise) are:
  • a moiety that is substituted is one in which one or more (for example one to four, alternatively from one to three and alternatively one or two) hydrogens have been independently replaced with another chemical substituent.
  • substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2-fluoro-3-propylphenyl.
  • substituted n-octyls include 2,4-dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl. Included within this definition are methylenes (-CH 2 -) substituted with oxygen to form carbonyl -CO-.
  • substituents When there are two optional substituents bonded to adjacent atoms of a ring structure, such as for example a phenyl, thiophenyl, or pyridinyl, the substituents, together with the atoms to which they are bonded, optionally form a 5- or 6- membered cycloalkyl or heterocycle having 1, 2, or 3 annular heteroatoms.
  • a hydrocarbyl, heteroalkyl, heterocyclic and/or aryl group is unsubstituted.
  • a hydrocarbyl, heteroalkyl, heterocyclic and/or aryl group is substituted with from 1 to 3 independently selected substituents.
  • substituents on alkenyl and alkynyl groups include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited as examples of alkyl substituents.
  • substituents on cycloalkyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited above as examples of alkyl substituents.
  • substituents include, but are not limited to, spiro-attached or fused cyclic substituents, for example spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
  • substituents on cycloalkenyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited as examples of alkyl substituents.
  • substituents include, but are not limited to, spiro-attached or fused cyclic substituents, especially spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
  • substituents on aryl groups include, but are not limited to, nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, cyano, alkyl or substituted alkyl, as well as those groups recited above as examples of alkyl substituents.
  • substituents include, but are not limited to, fused cyclic groups, especially fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalky, cylcoalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
  • substituents on aryl groups include, but are not limited to, haloalkyl and those groups recited as examples of alkyl substituents.
  • substituents on heterocyclic groups include, but are not limited to, spiro-attached or fused cylic substituents at any available point or points of attachment, for example spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloakenyl, fused heterocycle and fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.
  • a heterocyclic group is substituted on carbon, nitrogen and/or sulfur at one or more positions.
  • substituents on nitrogen include, but are not limited to alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, or aralkoxycarbonyl.
  • substituents on sulfur include, but are not limited to, oxo and C 1-6 alkyl.
  • nitrogen and sulfur heteroatoms may independently be optionally oxidized and nitrogen heteroatoms may independently be optionally quaternized.
  • substituents on ring groups include halogen, alkoxy and alkyl.
  • substituents on alkyl groups include halogen and hydroxy.
  • halohydrocarbyl as employed herein is a hydrocarbyl moiety, in which from one to all hydrogens have been replaced with halo.
  • halogen refers to chlorine, bromine, fluorine, or iodine.
  • acyl refers to an alkylcarbonyl or arylcarbonyl substituent.
  • acylamino refers to an amide group attached at the nitrogen atom ( i.e ., R-CO-NH-).
  • carbamoyl refers to an amide group attached at the carbonyl carbon atom ( i.e ., NH 2 -CO-).
  • the nitrogen atom of an acylamino or carbamoyl substituent is additionally optionally substituted.
  • sulfonamido refers to a sulfonamide substituent attached by either the sulfur or the nitrogen atom.
  • amino is meant to include NH 2 , alkylamino, dialkylamino (wherein the alkyl groups are independently selected), arylamino, and cyclic amino groups.
  • ureido refers to a substituted or unsubstituted urea moiety.
  • radical means a chemical moiety comprising one or more unpaired electrons.
  • substituents on cyclic moieties include 5- to 6-membered mono- and 9- to 14-membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system.
  • substituents on cyclic moieties also include 5- to 6-membered mono- and 9- to 14-membered bi-cyclic moieties attached to the parent cyclic moiety by a covalent bond to form a bi- or tri-cyclic bi-ring system.
  • an optionally substituted phenyl includes, but is not limited to, the following:
  • unsubstituted moiety e.g ., unsubstituted cycloalkyl, unsubstituted heteroaryl, etc.
  • an "unsubstituted” moiety means a moiety as defined above that does not have any optional substituents.
  • a saturated or unsaturated three- to eight-membered carbocyclic ring is for example a four- to seven-membered, alternatively five- or six-membered, saturated or unsaturated carbocyclic ring.
  • saturated or unsaturated three- to eight-membered carbocyclic rings include phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • a saturated or unsaturated three- to eight-membered heterocyclic ring contains at least one heteroatom selected from oxygen, nitrogen, and sulfur atoms.
  • the saturated or unsaturated three-to eight-membered heterocyclic ring for example contains one or two heteroatoms with the remaining ring-constituting atoms being carbon atoms.
  • the saturated or unsaturated three- to eight-membered heterocyclic ring is for example a saturated or unsaturated four- to seven-membered heterocyclic ring, alternatively a saturated or unsaturated five- or six-membered heterocyclic ring.
  • saturated or unsaturated three- to eight-membered heterocyclic groups include thienyl, pyridyl, 1,2,3-triazolyl, imidazolyl, isoxazolyl, pyrazolyl, piperazinyl, piperazino, piperidyl, piperidino, morpholinyl, morpholino, homopiperazinyl, homopiperazino, thiomorpholinyl, thiomorpholino, tetrahydropyrrolyl, and azepanyl.
  • a saturated or unsaturated carboxylic and heterocyclic group may condense with another saturated or heterocyclic group to form a bicyclic group, for example a saturated or unsaturated nine- to twelve-membered bicyclic carbocyclic or heterocyclic group.
  • Bicyclic groups include naphthyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, 1,4-benzoxanyl, indanyl, indolyl, and 1,2,3,4-tetrahydronaphthyl.
  • Carbocyclic or heterocyclic groups having this crosslinked structure include bicyclo[2.2.2]octanyl and norbornanyl.
  • D is an aromatic or heteroaromatic ring system, each of which is optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is substituted with one R 38 group.
  • D is a 5- or 6-membered aromatic or 5- or 6-membered heteroaromatic ring system, each of which is optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is a 6-membered aromatic or 6-membered heteroaromatic ring system, each of which is optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is a 6-membered aromatic ring system, optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is a 6-membered heteroaromatic ring system, optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is selected from the group consisting of wherein the members of said group are optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is selected from the group consisting of wherein the members of said group are optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is phenyl or pryidinyl, each of which is optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is phenyl, optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is pyridine, optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 groups.
  • D is phenyl, optionally substituted with one R 38 .
  • D is pyridine, optionally substituted with one R 38 .
  • D is phenyl, substituted with one R 38 .
  • D is pyridine, substituted with one R 38 .
  • each R 38 is independently selected from the group consisting of -(CH 1 ) j O(CH 1 ) i NR 36 R 39 , -(CH 1 ) n O(CH 2 ) ⁇ OR 37 , -(CH 2 ) n OR 37 , -(CH 2 ) n O(CH 2 ) j (C 6 -C 10 aryl), -(CH 2 ) n O(CH 2 ) i (5-10 membered heterocyclyl), -(CH 2 ) j NR 39 (CH 2 ) i NR 36 R 39 , -(CH 2 ) j NR 39 CH 2 C(O)NR 36 R 39 , -(CH 2 ) j NR 39 (CH 2 ) i NR 37 C(O)R 40 , -(CH 2 ) j NR 39 (CH 2 ) n O(CH 2 ) i OR 37 , -(CH 1 )
  • R 36 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, -(CH 2 ) n O(CH 2 ) i OR 37 , -(CH 2 ) n CN(CH 2 ) n OR 37 , -(CH 2 ) n CN(CH 2 ) n R 37 , and -(CH 2 ) n OR 37 , alternatively -(CH 2 ) n OR 37 , wherein each n is an integer independently ranging from 0 to 6 (alternatively 0 to 4, alternatively 0 to 2, alternatively 1 or 0, alternatively 0), and i is an integer ranging from 2 to 6.
  • each R 38 is independently C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 .
  • each R 38 is independently -(CH 1 ) j NR 39 (CH 1 ) n R 36 , wherein j is 1 and n is 2.
  • R 39 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, -OMe, -C(O)-C 1 -C 6 alkyl, -C(O)-O-C 1 -C 6 alkyl, -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups.
  • R 39 is a protecting group used to protect secondary amino groups, wherein said protecting group is selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • R 39 is H or C 1 -C 6 alkyl, alternatively H.
  • R 39 is selected from the group consisting of
  • D is optionally substituted with one or two (alternatively one) R 38 , wherein each said R 38 is independently selected from C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzylocycarbony
  • D is phenyl or pryidinyl (for example pyridinyl), optionally substituted with one or two (for example one) R 38 , wherein each said R 38 is independently selected from C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect
  • a 4 is O.
  • M is a structure selected from the group consisting of wherein
  • M is a structure selected from the group consisting of wherein
  • M is a structure selected from the group consisting of wherein
  • a 1 is S.
  • a 2 is -CH- or -C(CN)-.
  • a 3 is -C(R q )- or N, wherein R q is selected from the group consisting of H, halogen, NO 2 , cyano, OR r , NR r R r , CO 2 R r , C(O)NR r R r , SO 2 R r , SO 2 NR r R r , NR r SO 2 R r , NR r C(O)R r , NR r CO 2 R r , -CO(CH 2 ) 0-4 R r , -CONH(CH 2 ) 0-4 R r , alkylaminoalkyl, alkylaminoalkynyl, C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, alkenyl, substituted alkenyl, substituted alkenyl, substituted al
  • Z is selected from the group consisting of -O-, -S- and -NR 5 -, wherein R 5 is selected from the group consisting of H, an optionally substituted (C 1 -C 5 )acyl and C 1 -C 6 alkyl-O-C(O), wherein C 1 -C 6 alkyl is optionally substituted.
  • Z is -O-.
  • Ar is selected from the group consisting of phenyl, pyrazine, pyridazine, pryimidine and pyridine, wherein each of said phenyl, pyrazine, pyridazine, pryimidine and pyridine is optionally substituted with 0 to 4 R 2 groups.
  • Ar is phenyl, optionally substituted with 0 to 4 R 2 groups, alternatively with between zero and four halo.
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of wherein each methylene in any of the above formulae, other than those in a depicted ring, is independently optionally substituted with R 25 ;
  • a methylene group between two carbonyl groups is mono- or di-substituted with either an optionally substituted (C 1 -C 6 )alkyl or an optionally substituted spirocycle.
  • R 10 is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • any of E, E 1 , E 2 or E 3 are independently -NH-.
  • one of R 18a and R 19a is -CF 3 and the other is -H.
  • R 11 and R 12 are each -H.
  • X is S or O.
  • X is S.
  • R 13 is H.
  • R 11 , R 12 and R 13 are each -H.
  • X is O
  • one of R 18a and R 19a is -CF 3 and the other is -H
  • R 11 , R 12 and R 13 are each -H.
  • W is selected from the group consisting of wherein P 1 is a five- to seven-membered ring, including the two shared carbon atoms of the aromatic ring to which P 1 is fused, and wherein P 1 optionally contains between one and three heteroatoms.
  • W is selected from the group consisting of phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, indanyl, benzodio
  • W is selected from the group consisting of phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, indanyl, benzodio
  • W is phenyl, optionally substituted.
  • W is phenyl, optionally substituted with one or more of R 14a , R 15a , R 16a and R 17a .
  • W is substituted by a halogen and either an alkenyl or alkynyl.
  • W is phenyl substituted by a halogen and either an alkenyl or alkynyl.
  • Q is selected from the group consisting of wherein P 1 is a five- to seven-membered ring, including the two shared carbon atoms of the aromatic ring to which P 1 is fused, and wherein P 1 optionally contains between one and three heteroatoms.
  • Q is selected from the group consisting of phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, indanyl, benzodio
  • Q is phenyl, optionally substituted.
  • Q is phenyl, optionally substituted with one or more of R 20 .
  • Q is substituted by a halogen and either an alkenyl or alkynyl.
  • Q is phenyl substituted by a halogen and either an alkenyl or alkynyl.
  • R 14a and R 15a are both H
  • R 16a is C 2 -C 7 alkenyl or C 2 -C 6 alkynyl
  • R 17a is halogen, for example fluorine.
  • L 3 and L 4 are independently -CH- or N.
  • R 39 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, -OMe, -C(O)-C 1 -C 6 alkyl, -C(O)-O-C 1 -C 6 alkyl, -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups.
  • R 39 is a protecting group used to protect secondary amino groups, wherein said protecting group is selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • D is -(aryl), -(heterocycle) or -(heteroaryl), each of which is optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 group;
  • Z is -O-, -S-, -SO-, -SO 2 -, -CH 2 O-, -OCH 2 -, -CH 2 - or -N(R 5 )-, for example -O-;
  • Ar is aryl or heteroaryl, for example selected from the group consisting of phenyl, pyrazine, pyridazine, pryimidine and pyridine, for example phenyl, each of which is optionally substituted with 0 to 4 R 2 groups, alternatively with between zero and four halo; and wherein Q is optionally substituted with from 0 to 4 (alternatively 0 to 2, alternatively 1) independently selected R
  • D is optionally substituted with one or two (alternatively one) R 38 , wherein each said R 38 is independently C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 )nR 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzylocycarbony
  • D is phenyl or pyridinyl (for example pyridinyl), optionally substituted with one or two (alternatively one) R 38 , wherein each said R 38 is independently selected from C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used
  • R 39 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, -OMe, -C(O)-C 1 -C 6 alkyl, -C(O)-O-C 1 -C 6 alkyl, -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups.
  • R 39 is a protecting group used to protect secondary amino groups, wherein said protecting group is for example selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • said protecting group is for example selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • D is -(aryl), -(heterocycle) or -(heteroaryl), each of which is optionally substituted with 1 to 5 independently selected R 38 groups, alternatively 1 to 3 independently selected R 38 groups, and alternatively 1 or 2 independently selected R 38 group;
  • Z is -O-, -S-, -SO-, -SO 2 -, -CH 2 O-, -OCH 2 -, -CH 2 - or -N(R 5 )-, for example -O-;
  • Ar is aryl or heteroaryl, for example selected from the group consisting of phenyl, pyrazine, pyridazine, pyrimidine and pyridine, for example phenyl, each of which is optionally substituted with 0 to 4 R 2 groups, alternatively with between zero and four halo; and wherein said phenyl groups of G are optionally substituted with from 0 to 4 (alternatively 0 to
  • D is optionally substituted with one or two (alternatively one) R 38 , wherein each said R 38 is independently selected from C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 16 R 19 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z (alternatively H or C 1 -C 6 alkyl, alternatively H), -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect
  • D is phenyl or pyridinyl (for example pyridinyl), optionally substituted with one or two (alternatively one) R 38 , wherein each said R 38 is independently selected from C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z (alternatively H or C 1 -C 6 alkyl, alternatively H), -SO
  • R 39 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, -OMe, -C(O)-C 1 -C 6 alkyl, -C(O)-O-C 1 -C 6 alkyl, -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups.
  • R 39 is a protecting group used to protect secondary amino groups, wherein said protecting group is selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • D is phenyl or pryidinyl, substituted with one R 38 , wherein R 38 is -(CH 2 ) j NR 39 (CH 2 ) n R 36 , wherein j is an integer from 0 to 4, n is an integer from 0 to 6, R 39 is H or C 1 -C 6 alkyl, and R 36 is -(CH 2 ) n OR 37 , wherein n is an integer ranging from 0 to 6, and R 37 is H or C 1 -C 6 alkyl.
  • RG 2 is SCN- or HO-.
  • RG 1 is -NH 2 .
  • D is -(aryl) or -(heteroaryl);
  • Z is -O-, -S-, -SO-, -SO 2 -, -CH 2 O-, -OCH 2 - or -N(R 5 )-;
  • Ar is aryl or heteroaryl, each of which is optionally substituted with 0 to 4 R 2 groups.
  • D is optionally substituted phenyl or optionally substituted pyridinyl.
  • Z is O.
  • Ar is phenyl, pyrazine, pyridazine, pyrimidine or pyridine, each of which is optionally substituted.
  • Ar is optionally substituted phenyl.
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 , wherein j is an integer from 0 to 4, n is an integer from 0 to 6, R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z , -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z or -C(O)O-R z ), (alternatively
  • D is phenyl or pyridinyl
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 , wherein j is an integer from 0 to 4, n is an integer from 0 to 6,
  • R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R 2 , -C(O)-O-R z , -SO 1 -C 1 -C 6 alkyl and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z or -C(O
  • LG 1 and LG 2 are independently selected from the group consisting of halo, alkoxy, triflate, mesylate, tosylate, acetate, trifluoroacetate, SO 2 Me, nosylate, p-nitrophenolate and the like.
  • RG 1 is nitro, and said nitro is subsequently reduced to amino.
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z , -C(O)-O-R z and -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3
  • D is phenyl or pyridinyl (for example pyridinyl)
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2)
  • R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z , -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzy
  • R 39 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, -OMe, -C(O)-C 1 -C 6 alkyl, -C(O)-O-C 1 -C 6 alkyl, -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups.
  • R 39 is a protecting group used to protect secondary amino groups, wherein said protecting group is selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • R 38 is -(CH 2 ) n NR 39 (CH 2 ) m A 4 R 37 .
  • a pre-R 38 compound is an amino derivative of R 38 .
  • the amine precursor of -(CH 2 ) n NR 39 (CH 2 ) m A 4 R 37 is H 2 N(R 39 )(CH 2 ) m A 4 R 37 .
  • D is -(aryl)-, -(heterocycle)- or -(heteroaryl)-, for example phenyl or pyridinyl, each of which is optionally substituted.
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Mo
  • D is phenyl or pryidinyl (for example pyridinyl)
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2)
  • R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z and -C(O)-O-R z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbony
  • R 38 , D, M, Z and Ar are as defined above, wherein R 38 comprises zero or more reactive moieties therein, and RG 1 is a reactive group selected from the group consisting of nitro, -NH 2 , -NH-C 1 -C 4 alkyl-, -NH-C 2 -C 4 alkenyl, -NH-C 2 -C 4 alkynyl, -NH-C 3 -C 6 cycloalkyl, -OH, -SH, -NH-NH 2 , -NHOH, -N(Me)OH, -N(Me)NH 2 , -N(Me)-NHMe, -CH 2
  • RG 2 is -CHO or -CH 2 Hal; pre-R 38 is NH 2 (CH 2 ) m A 4 R 37 and R 38 is -(CH 2 ) n NH(CH 2 ) m A 4 R 37 .
  • R 38 is -(CH 2 ) n NR 39 (CH 2 ) m A 4 R 37 ;
  • D is -(aryl) or -(heteroaryl);
  • RG 2 is -CHO;
  • M is selected from the group consisting of
  • RG 1 is nitro, and said nitro is subsequently reduced to amino.
  • D is -(aryl) or -(heteroaryl); M is selected from the group consisting of
  • RG 1 is nitro, wherein said nitro is subsequently reduced to -NH 2 .
  • compound (E-1) is prepared by protection of an aldehyde of Formula (E-3): OHC-D-LG 1 (E-3).
  • D is phenyl or pyridinyl (for example pyridinyl).
  • D is aryl or heteroaryl, each of which is optionally substituted.
  • D is phenyl or pyridinyl, each of which is optionally substituted.
  • M is selected from the group consisting of wherein * represents the point of attachment to group D and ⁇ represents the point of group Z.
  • Z is O.
  • Ar is phenyl, optionally substituted with 0 to 4 R 2 .
  • G is a group B-L-T.
  • G is a group
  • G is selected from the group consisting of
  • G is selected from the group consisting of wherein any methylene group is independently optionally substituted with R 25 , wherein
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • G is selected from the group consisting of
  • R 38 is -(CH 2 ) n NH(CH 2 ) m A 4 R 37 or -(CH 2 ) n NR 36 R 39 .
  • RG 1 , RG 2 -G 1 and G are selected from the following combinations:
  • D is optionally substituted -(aryl), optionally substituted -(heterocyclyl) or optionally substituted -(heteroaryl), for example optionally substituted phenyl or optionally substituted pyridinyl (for example optionally substituted pyridinyl).
  • R 38 is C 1 -C 6 alkyl, -(CH 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2), R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R Z , -C(O)-O-R Z , -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups (for example tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-M
  • D is phenyl or pryidinyl (for example pyridinyl)
  • R 38 is C 1- C 6 alkyl, -(CF 2 ) j NR 39 (CH 2 ) n R 36 or -(CH 2 ) n NR 36 R 39 wherein j is an integer from 0 to 4 (alternatively 1 to 4, alternatively 1 or 2, alternatively 1), n is an integer from 0 to 6 (alternatively 2 to 6, alternatively 2 to 4, alternatively, 1 or 2)
  • R 39 is selected from the group consisting of H, -OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, -C(O)-R z , -C(O)-O-R Z , -SO 2 -C 1 -C 6 alkyl (alternatively H or C 1 -C 6 alkyl, alternatively H), and
  • R 39 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, -OMe, -C(O)-C 1 -C 6 alkyl, -C(O)-O-C 1 -C 6 alkyl, -SO 2 -C 1 -C 6 alkyl, and a protecting group used to protect secondary amino groups.
  • R 39 is a protecting group used to protect secondary amino groups, wherein said protecting group is selected from the group consisting of tert-butoxycarbonyl (Boc), benzylocycarbonyl (Cbz), F-Moc, -CH 2 Ph, -COCF 3 , -C(O)-R z and -C(O)O-R z .
  • D is -(aryl), -(heterocyclyl) or -(heteroaryl), each of which is optionally substituted.
  • LG 1 and LG 2 are independently selected from the group consisting of halo, alkoxy, triflate, mesylate, tosylate, acetate, trifluoroacetate, SO 2 Me, nosylate and p-nitrophenolate and the like.
  • D is phenyl or pryidinyl (for example pyridinyl).
  • R 39 is selected from the group consisting of
  • Certain compounds of the above formulas may generally be prepared according to the following Schemes. Tautomers and solvates (e.g., hydrates) of the compounds of the above formulas are also encompassed. Methods of solvation are generally known in the art. Accordingly, the compounds disclosed herein may be in the free, hydrate or salt form, and may be obtained by methods exemplified by the following schemes below.
  • steps involved in the processes optionally do not include chromatography, such as column chromatography.
  • R 39 is a cyclic moiety selected from the structures below:
  • toluene - EtOH, THF-acetone, IPA-MeCN) (for example in toluene-EtOH or in IPA-MeCN) in the temperature range from -10° to +120°C (for example 15-100°C), followed by deprotection of the Boc-protecting group in the intermediate V, are converted into the kinase inhibitors II [ WO 2006/019264 A1 , US 2006/0287343 A1 ].
  • Boc-Deprotection is carried out in acidic media such as TFA, AcOH, TFA/DCM, HCl/DCM, HCl/dioxane, AcOH/HCl, AcOH/HCl/H 2 O and the like (for example in TFA, HCl/dioxane, AcOH/HCl or AcOH/HCl/H 2 O).
  • acidic media such as TFA, AcOH, TFA/DCM, HCl/DCM, HCl/dioxane, AcOH/HCl, AcOH/HCl/H 2 O and the like (for example in TFA, HCl/dioxane, AcOH/HCl or AcOH/HCl/H 2 O).
  • the reactions proceed in aprotic solvents such as DMF, THF, DMSO, pyridine (etc.) (for example in DMF), at ambient temperatures in the presence of amide coupling reagents known in the art (EDC, HATU, HBTU, BOP, DCC, DIC, CIP, PyBOP, HNTU, AOP, PPAA, PFTU, etc.) (for example EDC and HATU) and tertiary amines (e.g. Et 3 N, DIPEA, N-methylmorpholine, N-methylpiperidine, DMAP, N,N-dimethylaniline, N,N-diethylaniline, DBU, DABCO, etc.) (for example DIPEA).
  • amide coupling reagents known in the art
  • EDC HATU, HBTU, BOP, DCC, DIC, CIP, PyBOP, HNTU, AOP, PPAA, PFTU, etc.
  • Boc-Deprotection is carried out in the same way as in the case of compounds II - in acidic media such as TFA, AcOH, TFA/DCM, HCl/DCM, HCl/dioxane, AcOH/HCl, AcOH/HCl/H 2 O and the like.
  • compounds III and IV may be prepared by a slightly different way from the compounds I using malonate derivatives such as aa2, aa3, aa4, and aa5, and anilines b as synthetic building blocks. It should also be understood that the alternative syntheses would involve hydrolysis of the alkyl ester functionalities as well as the Boc-deprotection steps.
  • preferred Alk Me, Et, iso-Pr, tert -Bu, benzyl etc.
  • the reductive amination products IX are then protected by a variety of protecting groups known in the art (e.g.” Protective Groups in Organic Synthesis” T. W. Greene, Wiley, NY ); to form compounds X.
  • protecting groups include but are not limited to acetyl-, trifluoroacetyl-, benzoyl-, tert -butoxycarbonyl (Boc), benzyloxycarbonyl, etc.
  • Heterocyclic Chem., 22, 1985, 1249-1252 using reagents such as n -BuLi, sec-BuLi LDA and like in the temperature range from -78°C to 15°C, for example from -15 to -5°C, followed by transmetallation with zinc chloride with a subsequent coupling to compounds X in the presence of a transition metal catalyst in the temperature range from 25 to 150°C, for example from 60 to 90°C to form chlorides XII.
  • the reactions are performed in aprotic solvents such as ether, THF, dioxane, benzene, toluene, xylenes, hexane, heptane.
  • reaction proceeds at elevated temperatures (100-200°C) in solvents such as DMF, DMA, DMSO, diphenyl ether, etc., in the presence of bases such as KH, K 2 CO 3 , NaH, Na 2 CO 3 , NaHCO 3 , tert- BuOK, etc.
  • bases such as KH, K 2 CO 3 , NaH, Na 2 CO 3 , NaHCO 3 , tert- BuOK, etc.
  • Reduction of the nitro group in XIII is achieved using standard procedures known in art. Examples of such procedures include but are not limited to catalytic hydrogenation, iron - ammonium chloride, zinc - ammonium chloride, nickel chloride-sodium borohydride, etc. in organic solvents (alcohols, AcOEt, DMA, DMF) or aqueous solutions or mixtures MeOH/water, EtOH/water or like.
  • the nitro aldehydes XVI undergo reductive amination by reacting with primary amines a4, to form the reductive amination products XVII.
  • the procedure is carried out under standard conditions ( Abdel-Magid A.F. et al, J.Org. Chem., 1996, 61, 3849-3862 ), at temperatures between -20 and +60°C in the presence of borohydride agents such as NaBH(OAc) 3 , NaBH 3 CN, NaBH 4 , in solvents such as DCE, DCM, AcOH or THF (or mixtures thereof).
  • the reductive amination products XVII are then protected by a variety of protecting groups known in the art (e.g.” Protective Groups in Organic Synthesis” T. W. Greene, Wiley, NY ) to form compounds XIII.
  • protecting groups include but are not limited to acetyl-, trifluoroacetyl-, benzoyl-, tert -butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), etc.
  • Heterocyclic kinase inhibitors II [ WO 2006/019264 A1 , US 2006/0287343 A1 ] can also be prepared from the anilino-compounds XVIII via a three-step reaction sequence shown in the scheme D.
  • solvents such as THF, acetone, toluene, DCM, CHCl 3 , MeCN, DMF, DMSO, alcohols (MeOH, EtOH, iso-PrOH etc.) (for example in THF), or in the mixtures of the listed solvents (e.g
  • Deprotection of the protected carbonyl group in XIX yields compounds XX; it is for example carried out in aqueous acidic media such as AcOH/water, TFA/water, TFA/acetone/water, HCl/acetone/water, HCl/THF/water HCl/dioxane/water and like.
  • Compounds XX undergo reductive amination by reacting with primary amines a4. The procedure is carried out under standard conditions ( Abdel-Magid A.F. et al, J.Org.
  • the kinase inhibitors III and IV [ US 2007/0004675 A1 ] can be prepared from the anilino-compounds XVIII. These transformations are shown in the schemes E and F.
  • anilines XVIII reacting either with a variety of substituted 1-(arylcarbamoyl)cyclopropanecarboxylic acids (a2, scheme E) or with a variety of substituted 3-oxo-3-(arylamino)propanoic acids (a3 scheme F) form compounds XXI and XXIII, respectively.
  • the reactions for example proceed in aprotic solvents such as DMF, THF, DMSO, pyridine (etc.) at ambient temperatures in the presence of amide coupling reagents known in the art (EDC, HATU, HBTU, BOP, DCC, DIC, CIP, PyBOP, HNTU, AOP, PPAA, PFTU, etc.) and tertiary amines (e.g. Et 3 N, DIPEA, N-methylmorpholine, N-methylpiperidine, DMAP, N,N-dimethylaniline, N,N-diethylaniline, etc.).
  • compounds III and IV may also be prepared from the compounds XVIII using malonate derivatives such as aa2, aa3, aa4, and aa5, and anilines b as synthetic building blocks. It should also be understood that the alternative syntheses would involve hydrolysis of the alkyl ester functionalities and acetal protecting groups.
  • Protected anilino derivatives XVIII can be prepared according to the general scheme G.
  • a variety of aromatic or heteroaromatic aldehydes VIII undergo reactions with alcohols to form protected species XXV (e.g.” Protective Groups in Organic Synthesis" T. W. Greene, Wiley, NY ).
  • the reactions are carried out under anhydrous conditions in solvents such as toluene, benzene, CHCl 3 at reflux in the presence of acids such as PTSA, CSA and like. Amberlyst or Dowex 50 can be used for such a purpose as well. Azeotropic removal of water facilitates the reactions.
  • Compounds XXVI can lead to the compounds XVIII either directly by replacing the chlorine atom in XXVI by 4-amino-2-fluorophenol at elevated temperatures (90-180°C) (for example 80 to 110 °C) in solvents such as DMF, DMA, DMSO, diphenyl ether, etc. in the presence of bases such as KH, K 2 CO 3 , NaH, Na 2 CO 3 , NaHCO 3 , NaHMDS, tert- BuOK , etc., or via the intermediate nitro compounds XXVII.
  • Nitro compounds XXVII can be obtained by replacing the chlorine atom in XXVI with 2-fluoro-4-nitrophenol.
  • reaction proceeds at elevated temperatures (120-200°C) in solvents such as DMF, DMA, DMSO, diphenyl ether, etc. in the presence of bases such as KH, K 2 CO 3 , NaH, Na 2 CO 3 , NaHCO 3 , tert- BuOK etc.
  • bases such as KH, K 2 CO 3 , NaH, Na 2 CO 3 , NaHCO 3 , tert- BuOK etc.
  • Reduction of the nitro group in XVIII can be achieved using standard procedures known in art. Examples of such procedures include iron - ammonium chloride, zinc - ammonium chloride, nickel chloride-sodium hydride, etc. in aqueous solutions or mixtures MeOH/water, EtOH/water or like, as well as the catalytic hydrogenation.
  • the recovered starting material was re-subjected to the reaction conditions except in acetic acid (5 ml), with 2-methoxyethylamine (8) (1 mL) and sodium trisacetoxyborohydride (0.030 g). After stirring for 5 min the mixture was concentrated. The residue was purified by Gilson Reverse Phase HPLC as before. The isolated product was combined with that above to produce compound 43 (0.13 g, 59 % yield) as a colorless solid.
  • the intermediate 51 (0.29 g, 0.62 mmol) was solubilized in EtOH (100 mL) and palladium on charcoal 10% (0.075 g) was added. The reaction mixture was stirred overnight under hydrogen atmosphere, filtered through a celite pad and the filtrate was concentrated under reduce pressure. The residue was purified by column chromatography with 60-80% EtOAc in hexanes to afford intermediate 52 (0.14 g, 52% yield) as a colorless solid. MS (m/z): 440.1 (M+H).
  • Step 2 N-(3-Fluoro-4-(2-(6-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2- b ]pyridin-7-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (62)
  • Step 2 2-(5-(1,3-Dioxan-2-yl)pyridin-2-yl)-7-chlorothieno[3,2- b ]pyridine (29)
  • Step 4 N -(4-(2-(5-(1,3-Dioxan-2-yl)pyridin-2-yl)thieno[3,2- b ]pyridin-7-yloxy)-3-fluorophenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (32)
  • Step 5 N -(3-Fluoro-4-(2-(5-formylpyridin-2-yl)thieno[3,2- b ]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (33)
  • Step 6 N -(3-Fluoro-4-(2-(5-((2-methoxyethoxy)methyl)pyridin-2-yl)thieno[3,2- b ]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (15)
  • Step 3 N-((6-(7-Chlorobenzo[ b ]thiophen-2-yl)pyridin-3-yl)methyl)-2-methoxy ethanamine (11)
  • Step 4 tert-Butyl (6-(7-(4-amino-2-fluorophenoxy)thieno[3,2- b ]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (13)
  • Step 5 tert-Butyl (6-(7-(2-fluoro-4-(3-(2-(4-fluorophenyl)acetyl)thioureido)phenoxy) thieno[3,2- b ]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (14)
  • Step 6 N -(3-Fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2- b ]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (15)
  • the layers were separated.
  • the organic phase was collected and extracted with 10% aqueous HCl (2x 100 mL).
  • the original aqueous phase (also acidic) and the acidic extracts were combined and basified to pH 9 with 4M NaOH (500 mL).
  • the basic solution was extracted with DCM (3x 200 mL).
  • the organic phase was collected, washed with water (3x 250 mL) and brine (400 mL) then concentrated to a volume of 100-120 mL.
  • THF 250 mL was added and the resultant solution was concentrated to a volume of 100-120 mL.
  • Pd(PPh 3 ) 4 (2.49 g, 2.15 mmol, 0.02eq.) was dissolved in the solution of tert-butyl (6-bromopyridin-3-yl)methyl(2-methoxyethyl)carbamate (10) (made during the step 2). This pooled solution was added to the reaction mixture which was heated at reflux for 1.5h. After cooling down to r.t., 2-MeTHF (400 mL), water (400 mL) and NH 4 OH (270 mL) were added. The mixture was stirred at r.t. for 30 min and the layers were separated. The aqueous phase was extracted with 2-MeTHF (2x 200 mL).
  • Step 4 tert-Butyl (6-(7-(4-amino-2-fluorophenoxy)thieno[3,2- b ]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (13)
  • Step 5 tert-Butyl (6-(7-(2-fluoro-4-(3-(2-(4-fluorophenyl)acetyl)thioureido)phenoxy)thieno[3,2- b ]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (14)
  • Step 6 N -(3-Fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2- b ]pyridine-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (15)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (2)

  1. Verbindung, ausgewählt aus der Gruppe, bestehend aus
    Figure imgb0151
  2. Verwendung einer Verbindung nach Anspruch 1 zum Herstellen einer kondensierten Verbindung des heterocyclischen Typs oder von Zwischenverbindungen, die bei der Herstellung der kondensierten Verbindung des heterocyclischen Typs verwendbar sind, wobei die kondensierte Verbindung des heterocyclischen Typs die Formel:
    Figure imgb0152
     aufweist.
EP11009425.7A 2007-08-29 2008-08-29 Verfahren und Zwischenverbindungen zur Herstellung kondensierter heterocyclischer Kinase-Hemmer Active EP2426108B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96867207P 2007-08-29 2007-08-29
EP08800257A EP2183255A4 (de) 2007-08-29 2008-08-29 Verfahren und zwischenprodukte zur herstellung von kondensierten heterocyclischen kinasehemmern

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08800257.1 Division 2008-08-29
EP08800257A Division EP2183255A4 (de) 2007-08-29 2008-08-29 Verfahren und zwischenprodukte zur herstellung von kondensierten heterocyclischen kinasehemmern

Publications (2)

Publication Number Publication Date
EP2426108A1 EP2426108A1 (de) 2012-03-07
EP2426108B1 true EP2426108B1 (de) 2016-08-10

Family

ID=40386629

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11009425.7A Active EP2426108B1 (de) 2007-08-29 2008-08-29 Verfahren und Zwischenverbindungen zur Herstellung kondensierter heterocyclischer Kinase-Hemmer
EP08800257A Withdrawn EP2183255A4 (de) 2007-08-29 2008-08-29 Verfahren und zwischenprodukte zur herstellung von kondensierten heterocyclischen kinasehemmern

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08800257A Withdrawn EP2183255A4 (de) 2007-08-29 2008-08-29 Verfahren und zwischenprodukte zur herstellung von kondensierten heterocyclischen kinasehemmern

Country Status (4)

Country Link
US (3) US8907091B2 (de)
EP (2) EP2426108B1 (de)
ES (1) ES2593279T3 (de)
WO (1) WO2009026720A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473501B1 (de) * 2009-09-03 2019-02-20 Allergan, Inc. Verbindungen als tyrosinkinasemodulatoren
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
MX2012012031A (es) 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
US10600235B2 (en) 2012-02-23 2020-03-24 Charles D. Huston System and method for capturing and sharing a location based experience
EP2817785B1 (de) 2012-02-23 2019-05-15 Charles D. Huston System und verfahren zur erzeugung einer umgebung und zur gemeinsamen nutzung einer ortsbasierten erfahrung in einer umgebung
JP6351993B2 (ja) 2013-03-18 2018-07-04 芝浦メカトロニクス株式会社 基板処理装置及び基板処理方法
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
MY195799A (en) 2014-12-18 2023-02-21 Genzyme Corp Pharmaceutical Formulations of Tropomyosin-Related Kinase (TRK) Inhibitors
UY36462A (es) 2014-12-23 2016-07-29 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
EP3472161B1 (de) 2016-06-20 2020-03-25 Novartis AG Triazolopyridinverbindungen und verwendungen davon
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
CA3072169C (en) * 2018-03-08 2022-04-19 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
CA3113233A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN114401720A (zh) * 2019-09-10 2022-04-26 米拉蒂治疗股份有限公司 多酪氨酸激酶抑制剂的晶型、制备方法及其用途
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
WO2023283369A1 (en) 2021-07-08 2023-01-12 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
AU2005266803B2 (en) * 2004-07-30 2011-10-27 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
KR20070052755A (ko) 2004-08-17 2007-05-22 엘지전자 주식회사 데이터 재생을 위한 합성 파일 구조 구성 방법, 및 이러한합성 파일 구조를 사용하여 데이터를 재생하는 방법 및장치
AU2005302499A1 (en) * 2004-10-28 2006-05-11 Bayer Cropscience Ag Insecticidal N,N-di(heteroarylalkyl) amine derivatives
GB0500828D0 (en) * 2005-01-15 2005-02-23 Astrazeneca Ab Benzamide derivatives
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
EP1989211A2 (de) * 2006-01-30 2008-11-12 Array Biopharma, Inc. Heterocyclische thiophenverbindungen und verfahren zu ihrer verwendung
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
US8907091B2 (en) 2014-12-09
WO2009026720A1 (en) 2009-03-05
EP2183255A1 (de) 2010-05-12
US9018378B2 (en) 2015-04-28
EP2426108A1 (de) 2012-03-07
EP2183255A4 (de) 2011-06-15
US8569503B2 (en) 2013-10-29
ES2593279T3 (es) 2016-12-07
US20090286984A1 (en) 2009-11-19
US20120095234A1 (en) 2012-04-19
US20130310564A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
EP2426108B1 (de) Verfahren und Zwischenverbindungen zur Herstellung kondensierter heterocyclischer Kinase-Hemmer
EP2183254B1 (de) Inhibitoren der proteintyrosinkinaseaktivität
AU2010246540B2 (en) Inhibitors of protein tyrosine kinase activity
WO2008046216A1 (en) Kinase inhibitors and uses thereof
CA3054324C (en) Tri-cycle compound and applications thereof
CA2611370A1 (en) Inhibitors of vegf receptor and hgf receptor signaling
JP6774578B2 (ja) Ｍｅｋ阻害剤としてのクマリン環系化合物およびその応用。
WO2009100536A1 (en) Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
CA2796008A1 (en) Inhibitors of protein tyrosine kinase activity
EP3956327A1 (de) Chirale indolverbindungen und deren verwendung
KR20240115232A (ko) Sik3 억제제 및 이의 중간체를 제조하기 위한 합성 반응식 및 과정
JP4733648B2 (ja) マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体
JP4871273B2 (ja) ４−トリフルオロメトキシフェノキシベンゾール−４’−スルホン酸、その製造法および薬剤としての使用
KR101315788B1 (ko) 매트릭스 메탈로프로테이나제의 억제제로서 사용하기 위한테트라하이드로푸란 유도체
WO2019106087A1 (en) Ampk inhibitors
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 2183255

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ISAKOVIC, LJUBOMIR

Inventor name: VAISBURG, ARKADII

Inventor name: RAEPPEL, FRANCK

Inventor name: CLARIDGE, STEPHEN, WILLIAM

Inventor name: MANNION, MICHAEL

Inventor name: GRANGER, MARIE-CLAUDE

Inventor name: ZHAN, LIJIE

Inventor name: NANTEL, MIGUEL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAEPPEL, FRANCK

Inventor name: ZHAN, LIJIE

Inventor name: VAISBURG, ARKADII

Inventor name: GRANGER, MARIE-CLAUDE

Inventor name: ISAKOVIC, LJUBOMIR

Inventor name: CLARIDGE, STEPHEN, WILLIAM

Inventor name: MANNION, MICHAEL

Inventor name: NANTEL, MIGUEL

17P Request for examination filed

Effective date: 20120905

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: METHYLGENE INC.

17Q First examination report despatched

Effective date: 20150714

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160104

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160530

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2183255

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 818885

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008045650

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2593279

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20161207

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160810

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 818885

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161210

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161111

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161212

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008045650

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161110

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

26N No opposition filed

Effective date: 20170511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160829

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160829

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160810

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20221103 AND 20221109

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240702

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240701

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240702

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240909

Year of fee payment: 17

Ref country code: CH

Payment date: 20240903

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240710

Year of fee payment: 17

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: MIRATI THERAPEUTICS, INC.

Effective date: 20241122

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN